Xbrane Biopharma Reclaims Rights of BIIB801 (Biosimilar, Cimzia) from Biogen
Shots:
- Xbrane Biopharma will reclaim full rights of BIIB801 from Biogen after the termination of their commercialization and license agreement. BIIB801 is a biosimilar version of Cimzia (certolizumab pegol), under non-clinical development
- The agreement was signed b/w Xbrane & Biogen in Feb 2022, under which Xbrane received a non-refundable $8M upfront. It has been terminated due to Biogen's strategic review and Xbrane will get full rights to the program
- Xbrane has begun an out-licensing process to find a new development & commercialization partner & has received significant interest for the same. The production has been scaled up with Xbrane’s contract manufacturer, with clinical material production in 2024, enabling clinical trials in 2025
Ref: Xbrane | Image: Xbrane
Related News:- Xbrane Biopharma and STADA Team Up with Valorum Biologics for Commercializing Xlucane (Biosimilar, Ranibizumab) Across the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
